A First-in-Human, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-925 in Healthy Adult and Elderly Volunteers and Patients with Narcolepsy

Trial Profile

A First-in-Human, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-925 in Healthy Adult and Elderly Volunteers and Patients with Narcolepsy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2018

At a glance

  • Drugs TAK-925 (Primary)
  • Indications Atopic dermatitis; Cognition disorders; Migraine; Obsessive-compulsive disorders; Psychotic disorders
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Takeda
  • Most Recent Events

    • 17 Apr 2018 Planned number of patients changed from 48 to 56.
    • 05 Feb 2018 Planned primary completion date changed from 24 Sep 2018 to 26 Sep 2018.
    • 01 Feb 2018 Planned End Date changed from 24 Sep 2018 to 26 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top